Unknown PHASE2 INTERVENTIONAL 1-arm NCT03532737

Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer

Phase II Non-Randomised Controlled Trial Of Concomitant Immune Check Point Inhibitor With Radiotherapy And Chemotherapy Or Cetuximab In Advanced Non Metastatic Head And Neck Cancer

Sponsor: Kuwait Cancer Control Center

Conditions Locally Advanced Head and Neck Cancer

Interventions Pembrolizumab

Updated 11 times since 2018 Last updated: Jan 21, 2024 Started: Oct 7, 2018 Primary completion: Sep 30, 2025 Completion: Oct 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Locally Advanced Head and Neck Cancer and is currently ongoing. Kuwait Cancer Control Center leads this study, which shows 11 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

11 versions recorded

Feb 2026 — Present [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2025 — Feb 2026 [monthly]

Recruiting PHASE2
Sep 2024 — Sep 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Feb 2024 — Jul 2024 [monthly]

Recruiting PHASE2

▶ Show 6 earlier versions

Nov 2023 — Feb 2024 [monthly]

Recruiting PHASE2
May 2021 — Nov 2023 [monthly]

Recruiting PHASE2
Jan 2021 — May 2021 [monthly]

Recruiting PHASE2
Oct 2020 — Jan 2021 [monthly]

Recruiting PHASE2
Nov 2018 — Oct 2020 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jun 2018 — Nov 2018 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kuwait Cancer Control Center

Data source: Kuwait Cancer Control Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kuwait City, Kuwait